Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)
The anti-interleukin-23 antibody guselkumab (GUS) demonstrated favourable week 24 efficacy and safety over fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis (study part I).To compare, in study part II, the sustainability of treatment responses (...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2024
|
| In: |
British journal of dermatology
Year: 2024, Jahrgang: 191, Heft: 1, Pages: 36-48 |
| ISSN: | 1365-2133 |
| DOI: | 10.1093/bjd/ljad523 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/bjd/ljad523
|
| Verfasserangaben: | Diamant Thaçi, Andreas Pinter, Michael Sebastian, Christian Termeer, Michael Sticherling, Sascha Gerdes, Knut Schäkel, Sven Wegner, Stefanie Krampe, Holger Bartz, Christian Rausch, Friedemann Taut, Kilian Eyerich |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1909896233 | ||
| 003 | DE-627 | ||
| 005 | 20250716213121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bjd/ljad523 |2 doi | |
| 035 | |a (DE-627)1909896233 | ||
| 035 | |a (DE-599)KXP1909896233 | ||
| 035 | |a (OCoLC)1528014394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Thaçi, Diamant |e VerfasserIn |0 (DE-588)1349744921 |0 (DE-627)190989673X |4 aut | |
| 245 | 1 | 0 | |a Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters |b results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS) |c Diamant Thaçi, Andreas Pinter, Michael Sebastian, Christian Termeer, Michael Sticherling, Sascha Gerdes, Knut Schäkel, Sven Wegner, Stefanie Krampe, Holger Bartz, Christian Rausch, Friedemann Taut, Kilian Eyerich |
| 264 | 1 | |c July 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht: 22. Dezember 2023 | ||
| 500 | |a Gesehen am 29.11.2024 | ||
| 520 | |a The anti-interleukin-23 antibody guselkumab (GUS) demonstrated favourable week 24 efficacy and safety over fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis (study part I).To compare, in study part II, the sustainability of treatment responses (weeks 24-32) in GUS- and FAE-treated patients and treatment responses (weeks 32-56) in patients treated with GUS and FAE and in FAE nonresponders switching to GUS; and, in part III, to investigate the maintenance of response through week 100 in patients withdrawn from GUS at week 56.At week 0, systemic treatment-naïve patients were randomized 1 : 1 to GUS or FAE as per label. At week 32, patients with a Psoriasis Area and Severity Index (PASI) 75 (≥ 75% improvement in PASI score) response (r) continued assigned treatment (GUSr-GUS; FAEr-FAE), whereas nonresponders (nr) received GUS (FAEnr-GUS; GUSnr-GUS). GUS-treated patients with a week 56 PASI 90 response (≥ 90% improvement in PASI score) were withdrawn (w) and followed until loss of response or week 100.At week 32, 98% (n = 54/55) of GUS- and 41% (n = 14/34) of FAE-treated patients were PASI 75 responders. At week 56, 91%, 50% and 80% of GUSr-GUS, FAEr-FAE and FAEnr-GUS patients, respectively, achieved a PASI 90 response; 72%, 29% and 45%, respectively, achieved a Dermatology Life Quality Index score of 0/1. At week 100, 44 weeks postwithdrawal, 47% (n = 17/36) and 25% (n = 3/12) of GUS-GUSw and FAEGUSw patients, respectively, maintained a PASI score ≤ 5. Overall, the adverse event and discontinuation rates were lower for GUS than FAE.In these exploratory analyses, GUS, as a first-line systemic treatment or second-line systemic treatment in FAE nonresponders, was associated with long-term clinical efficacy up to week 100, including a withdrawal period. | ||
| 700 | 1 | |8 1\p |a Pinter, Andreas |d 1979- |e VerfasserIn |0 (DE-588)1071806246 |0 (DE-627)826332099 |0 (DE-576)433308338 |4 aut | |
| 700 | 1 | |a Sebastian, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Termeer, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |8 2\p |a Sticherling, Michael |e VerfasserIn |0 (DE-588)1048396029 |0 (DE-627)780305507 |0 (DE-576)402198069 |4 aut | |
| 700 | 1 | |8 3\p |a Gerdes, Sascha |d 1976- |e VerfasserIn |0 (DE-588)132178818 |0 (DE-627)519023064 |0 (DE-576)298988976 |4 aut | |
| 700 | 1 | |a Schäkel, Knut |e VerfasserIn |0 (DE-588)1032757418 |0 (DE-627)739272896 |0 (DE-576)251064476 |4 aut | |
| 700 | 1 | |a Wegner, Sven |e VerfasserIn |4 aut | |
| 700 | 1 | |8 4\p |a Krampe, Stefanie |d 1972- |e VerfasserIn |0 (DE-588)123167116 |0 (DE-627)706190017 |0 (DE-576)293586586 |4 aut | |
| 700 | 1 | |8 5\p |a Bartz, Holger |d 1972- |e VerfasserIn |0 (DE-588)171933389 |0 (DE-627)69682471X |0 (DE-576)132811723 |4 aut | |
| 700 | 1 | |a Rausch, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taut, Friedemann |e VerfasserIn |0 (DE-588)1106268733 |0 (DE-627)86296380X |0 (DE-576)174871112 |4 aut | |
| 700 | 1 | |a Eyerich, Kilian |d 1979- |e VerfasserIn |0 (DE-588)133076814 |0 (DE-627)533325765 |0 (DE-576)299606821 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of dermatology |d Oxford : Oxford University Press, 1951 |g 191(2024), 1 vom: Juli, Seite 36-48 |h Online-Ressource |w (DE-627)320433803 |w (DE-600)2004086-6 |w (DE-576)091140285 |x 1365-2133 |7 nnas |a Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS) |
| 773 | 1 | 8 | |g volume:191 |g year:2024 |g number:1 |g month:07 |g pages:36-48 |g extent:13 |a Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS) |
| 856 | 4 | 0 | |u https://doi.org/10.1093/bjd/ljad523 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 5\p |a cgwrk |d 20250301 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20241129 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 1032757418 |a Schäkel, Knut |m 1032757418:Schäkel, Knut |d 910000 |d 911300 |e 910000PS1032757418 |e 911300PS1032757418 |k 0/910000/ |k 1/910000/911300/ |p 7 | ||
| 999 | |a KXP-PPN1909896233 |e 4627704917 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)British journal of dermatology","corporate":[{"role":"isb","display":"British Association of Dermatologists"}],"part":{"issue":"1","volume":"191","extent":"13","text":"191(2024), 1 vom: Juli, Seite 36-48","pages":"36-48","year":"2024"},"note":["Gesehen am 03.07.25"],"titleAlt":[{"title":"BJD"}],"origin":[{"publisher":"Oxford University Press ; Blackwell Science ; Blackwell ; Wiley-Blackwell","dateIssuedKey":"1951","publisherPlace":"Oxford ; Oxford [u.a.] ; Oxford [u.a.] ; Oxford","dateIssuedDisp":"1951-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"subtitle":"BJD ; the journal of the British Association of Dermatologists","title_sort":"British journal of dermatology","title":"British journal of dermatology"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"320433803","pubHistory":["Volume 63, issue 1 (January 1951)-"],"id":{"zdb":["2004086-6"],"issn":["1365-2133"],"eki":["320433803"],"doi":["10.1111/(ISSN)1365-2133"]}}],"id":{"eki":["1909896233"],"doi":["10.1093/bjd/ljad523"]},"recId":"1909896233","name":{"displayForm":["Diamant Thaçi, Andreas Pinter, Michael Sebastian, Christian Termeer, Michael Sticherling, Sascha Gerdes, Knut Schäkel, Sven Wegner, Stefanie Krampe, Holger Bartz, Christian Rausch, Friedemann Taut, Kilian Eyerich"]},"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"language":["eng"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"July 2024"}],"note":["Veröffentlicht: 22. Dezember 2023","Gesehen am 29.11.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters","subtitle":"results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)","title":"Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters"}],"person":[{"given":"Diamant","role":"aut","family":"Thaçi","display":"Thaçi, Diamant"},{"display":"Pinter, Andreas","family":"Pinter","role":"aut","given":"Andreas"},{"role":"aut","given":"Michael","family":"Sebastian","display":"Sebastian, Michael"},{"given":"Christian","role":"aut","display":"Termeer, Christian","family":"Termeer"},{"display":"Sticherling, Michael","family":"Sticherling","role":"aut","given":"Michael"},{"family":"Gerdes","display":"Gerdes, Sascha","given":"Sascha","role":"aut"},{"role":"aut","given":"Knut","display":"Schäkel, Knut","family":"Schäkel"},{"display":"Wegner, Sven","family":"Wegner","role":"aut","given":"Sven"},{"given":"Stefanie","role":"aut","display":"Krampe, Stefanie","family":"Krampe"},{"role":"aut","given":"Holger","family":"Bartz","display":"Bartz, Holger"},{"family":"Rausch","display":"Rausch, Christian","given":"Christian","role":"aut"},{"display":"Taut, Friedemann","family":"Taut","given":"Friedemann","role":"aut"},{"display":"Eyerich, Kilian","family":"Eyerich","given":"Kilian","role":"aut"}]} | ||
| SRT | |a THACIDIAMAGUSELKUMAB2024 | ||